DoJ Probes Big Orthopedic Firms’ Pricing, Deflating Investor Confidence
This article was originally published in The Gray Sheet
Executive Summary
The U.S. Department of Justice served subpoenas to the five largest orthopedic manufacturers to investigate suspected industry violations of antitrust laws in pricing hip and knee implants. The specific nature of the inquiry is unknown
You may also be interested in...
Biomet subpoenaed
Orthopedic device maker receives a Department of Justice subpoena from the U.S. Attorney for the Southern District of West Virginia for documents related to products marketed and sold by the company's EBI division - now doing business as Biomet Spine and Biomet Trauma - from January 1999 through the present. The company stated May 25 that the subpoena relates to a "limited number of products currently manufactured." Over the last two years, Biomet, Johnson & Johnson/DePuy, Zimmer and Stryker all received subpoenas related to the Justice Department's ongoing investigations into possible anti-trust issues and alleged improper financial relationships with doctors (1"The Gray Sheet" July 3, 2006, p. 8)...
Biomet subpoenaed
Orthopedic device maker receives a Department of Justice subpoena from the U.S. Attorney for the Southern District of West Virginia for documents related to products marketed and sold by the company's EBI division - now doing business as Biomet Spine and Biomet Trauma - from January 1999 through the present. The company stated May 25 that the subpoena relates to a "limited number of products currently manufactured." Over the last two years, Biomet, Johnson & Johnson/DePuy, Zimmer and Stryker all received subpoenas related to the Justice Department's ongoing investigations into possible anti-trust issues and alleged improper financial relationships with doctors (1"The Gray Sheet" July 3, 2006, p. 8)...
Biomet Accepts $10.9 Bil. Private Equity Buyout To Stay Independent
Orthopedic device makers Smith & Nephew and Biomet ended discussions on a possible merger after Biomet announced plans to become a private, independent company by the end of October